Regional variability of imaging biomarkers in autosomal dominant Alzheimer's disease
Open accessThe DOI matches its Crossref record; 96 of the 97 references it cites were found in a registry or an index.
Abstract
Significance: Beta-amyloid plaque accumulation, glucose hypometabolism, and neuronal atrophy are hallmarks of Alzheimer’s disease. However, the regional ordering of these biomarkers prior to dementia remains untested. In a cohort with Alzheimer’s disease mutations, we performed an integrated whole-brain analysis of three major imaging techniques: amyloid PET, [ 18 F]fluro-deoxyglucose PET, and structural MRI. We found that most gray-matter structures with amyloid plaques later have hypometabolism followed by atrophy. Critically, however, not all regions lose metabolic function, and not all regions atrophy, even when there is significant amyloid deposition. These regional disparities have important implications for clinical trials of disease-modifying therapies.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“and that progression of biomarker measures is also a continuous process that begins before symptoms [9–14]”
From NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease (2018) · cites this paper as [10]
In the citing paper
“The first biomarkers to become abnormal in carriers of deterministic AD mutations are those of Aβ [9–11,14].”
From NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease (2018) · cites this paper as [10]
In the citing paper
“Nevertheless, neuroimaging and biomarker studies show consistencies in the sequential onset of amyloid deposition, tau, FDG-PET hypometabolism, grey matter atrophy, and clinical presentation between late-onset and autosomal-dominant Alzheimer’s disease (Bateman et al., 2012; Benzinger et al., 2013; Young et al., 2014; Gordon et al., 2018; Oxtoby et al., 2018), suggesting substantial commonalities”
From White matter diffusion alterations precede symptom onset in autosomal dominant Alzheimer’s disease (2018) · cites this paper as Benzinger et al., 2013
In the citing paper
“Since the precuneus region has been shown to be most sensitive to Alzheimer’s disease pathophysiology in autosomal-dominant Alzheimer’s disease2,24, we focused our analyses on this region a priori.”
From Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer’s disease (2019) · cites this paper as [24]
In the citing paper
“ADAD work has revealed a temporal ordering of biomarkers consistent with theoretical models,6–8 and indications that pathology progressively appears in new regions of the brain as the disease worsens7.”
From Spatial patterns of neuroimaging biomarker change in individuals from families with autosomal dominant Alzheimer's disease: a longitudinal study (2018) · cites this paper as [7]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123 · cited 1×
“Our results are also consistent with the neuropathological studies that have found differential temporal ordering of the formation of amyloid plaques and neurofibrillary tangles (25, 26).”
Resultggplot2: Elegant Graphics for Data Analysis
Wickham, H. (2009) · doi:10.1007/978-0-387-98141-3 · Cited by 14,447
Desikan, R. S., Ségonne, F., Fischl, B., Quinn, B. T., Dickerson, B. C., Blacker, D., Buckner, R. L., Dale, A. M., Maguire, R. P., Hyman, B. T., et al. (2006) · NeuroImage · doi:10.1016/j.neuroimage.2006.01.021 · Cited by 13,324 · cited 1×
“Each voxel in the brain was assigned an anatomical label (53, 79).”
MethodA default mode of brain function
Raichle, M. E., MacLeod, A. M., Snyder, A. Z., Powers, W. J., Gusnard, D. A., & Shulman, G. L. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.98.2.676 · Cited by 12,190 · cited 2×
“As previously reported (18), the most commonly affected areas across modalities bear a striking resemblance to the default mode network (20) Furthermore, studies in LOAD have found spreading patterns of atrophy (21, 22), hypometabolism (23), and amyloid deposition (24) as a correlate of increasing disease severity.”
BackgroundSelf-citationRobust Locally Weighted Regression and Smoothing Scatterplots
Cleveland, W. S. (1979) · Journal of the American Statistical Association · doi:10.1080/01621459.1979.10481038 · Cited by 11,594 · cited 1×
“To estimate the trajectory of biomarker changes, curves were fit to the cross-sectional data using LOESS regression (91).”
Methodnlme : Linear and nonlinear mixed effects models
DebRoy, S. (2006) · Medical Entomology and Zoology · Cited by 10,009
The Clinical Dementia Rating (CDR): Current version and scoring rules
Morris, J. C. (1993) · Neurology · doi:10.1212/wnl.43.11.2412-a · Cited by 9,882
Self-citationFischl, B. (2012) · NeuroImage · doi:10.1016/j.neuroimage.2012.01.021 · Cited by 9,526
Random-Effects Models for Longitudinal Data
Laird, N. M., & Ware, J. H. (1982) · Biometrics · doi:10.2307/2529876 · Cited by 8,923
Fischl, B., Salat, D. H., Busa, E., Albert, M., Dieterich, M., Haselgrove, C., van der Kouwe, A., Killiany, R., Kennedy, D., Klaveness, S., et al. (2002) · Neuron · doi:10.1016/s0896-6273(02)00569-x · Cited by 8,610
Cited by
NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease
Jack, C. R., Bennett, D. A., Blennow, K., Carrillo, M. C., Dunn, B., Haeberlein, S. B., Holtzman, D. M., Jagust, W., Jessen, F., Karlawish, J., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.02.018 · Cited by 10,537
Self-citationRevised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup
Jack, C. R., Andrews, J. S., Beach, T. G., Buracchio, T., Dunn, B., Graf, A., Hansson, O., Ho, C., Jagust, W., McDade, E., et al. (2024) · Alzheimer's & Dementia · doi:10.1002/alz.13859 · Cited by 2,803
Self-citationBlood-Brain Barrier: From Physiology to Disease and Back
Sweeney, M. D., Zhao, Z., Montagne, A., Nelson, A. R., & Zlokovic, B. V. (2019) · Physiological Reviews · doi:10.1152/physrev.00050.2017 · Cited by 2,312
Mitochondria dysfunction in the pathogenesis of Alzheimer’s disease: Recent advances.
Wang, W., Zhao, F., Ma, X., Perry, G., & Zhu, X. (2020) · Molecular Neurodegeneration · doi:10.1186/s13024-020-00376-6 · Cited by 1,274
Amyloid β-based therapy for Alzheimer’s disease: Challenges, successes and future
Zhang, Y., Chen, H., Li, R., Sterling, K., & Song, W. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01484-7 · Cited by 988
“Late application PET imaging allows us to visualize Aβ fibrils in patients, which accumulate in an Alzheimer’s brain as early as 15 years before the onset of symptoms.(477) A change in CSF Aβ levels can be detected even up to 25 years before a patient begins to show symptoms.”
Background
Metadata
- Authors
- Benzinger, T. L. S., Blazey, T., Jack, C. R., Koeppe, R. A., Su, Y., Xiong, C., Raichle, M. E., Snyder, A. Z., Ances, B. M., Bateman, R. J., Cairns, N. J., Fagan, A. M., Goate, A., Marcus, D. S., Aisen, P. S., Christensen, J. J., Ercole, L., Hornbeck, R. C., Farrar, A. M., Aldea, P., Jasielec, M. S., Owen, C. J., Xie, X., Mayeux, R., Brickman, A., McDade, E., Klunk, W., Mathis, C. A., Ringman, J., Thompson, P. M., Ghetti, B., Saykin, A. J., Sperling, R. A., Johnson, K. A., Salloway, S., Correia, S., Schofield, P. R., Masters, C. L., Rowe, C., Villemagne, V. L., Martins, R., Ourselin, S., Rossor, M. N., Fox, N. C., Cash, D. M., Weiner, M. W., Holtzman, D. M., Buckles, V. D., Moulder, K., & Morris, J. C.
- Affiliations
- Washington University in St. Louis (US)
- Departments of aRadiology,
- Mayo Clinic (US)
- University of Michigan (US)
- Biostatistics,
- Neurology,
- Pathology and Immunology, and
- University of California San Diego (US)
- Columbia University Irving Medical Center (US)
- Departments of jNeurology,
- University of Pittsburgh (US)
- Department of Neurology, Easton Center for Alzheimer’s Disease Research and
- University of California, Los Angeles (US)
- Department of Pathology and Laboratory Medicine, and
- Indiana University Indianapolis (US)
- Harvard University (US)
- Brown University (US)
- UNSW Sydney (AU)
- Mental Health Research Institute (AU)
- Austin Hospital (AU)
- Edith Cowan University (AU)
- Dementia Research Centre, Institute of Neurology, University College London, London WC1N 3GB, United Kingdom; and
- UCL Queen Square Institute of Neurology (GB)
- San Francisco VA Medical Center (US)
- ORCID
- Benzinger, Tammie L. S.
- Blazey, Tyler
- Jack, Clifford R.
- Koeppe, Robert A.
- Su, Yi
- Xiong, Chengjie
- Raichle, Marcus E.
- Snyder, Abraham Z.
- Ances, Beau M.
- Bateman, Randall J.
- Fagan, Anne M.
- Goate, Alison
- Marcus, Daniel S.
- Hornbeck, Russ C.
- Mayeux, Richard
- Brickman, Adam
- McDade, Eric
- Klunk, William
- Mathis, Chester A.
- Ringman, John
- Thompson, Paul M.
- Ghetti, Bernardino
- Saykin, Andrew J.
- Sperling, Reisa A.
- Johnson, Keith A.
- Salloway, Stephen
- Correia, Stephen
- Schofield, Peter R.
- Masters, Colin L.
- Rowe, Christopher
- Villemagne, Victor L.
- Martins, Ralph
- Rossor, Martin N.
- Fox, Nick C.
- Cash, David M.
- Weiner, Michael W.
- Holtzman, David M.
- Morris, John C.
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2013-11-05
- Volume
- 110
- Issue
- 47
- Pages
- E4502-9
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC3839740
- OpenAlex
- W2053288220
- Cited by
- 391
- References
- 97
- Citations by year
- 2026: 19 · 2025: 32 · 2024: 22 · 2023: 24 · 2022: 21 · 2021: 45 · 2020: 36 · 2019: 19 · 2018: 47 · 2017: 33 · 2016: 32 · 2015: 40 · 2014: 20 · 2013: 1
- FWCI
- 22.04
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Minerva Access (University of Melbourne) (submittedVersion)
- Research Online (Edith Cowan University) (submittedVersion)
- Funders
- National Institute for Health and Care Research (NF-SI-0512-10033, NF-SI-0508-10123)
- National Institutes of Health (1s10rr022984-01a1, UL1TR000448)
- National Institute on Aging (U19AG032438, U24AG021886)
- National Institute of Nursing Research (R01NR012657)
- National Institute of General Medical Sciences (T32GM008151)
- National Institute of Neurological Disorders and Stroke (P30NS048056)
- National Institute of Biomedical Imaging and Bioengineering (P41EB015922)
- National Center for Research Resources (S10 RR022984, 1S10RR022984-01A1)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Medical Imaging Techniques and Applications
- Keywords
- autosomal dominant Alzheimer's disease, imaging biomarkers, amyloid deposition, Pittsburgh compound B PET, FDG-PET, glucose metabolism, cortical thinning, brain atrophy, hypermetabolism, precuneus, posterior cingulate cortex, symptom onset, longitudinal disease progression, mutation carriers
- MeSH terms
- Adult, Alzheimer Disease, Aniline Compounds, Brain, Carbon Radioisotopes, Female, Genes, Dominant, Humans, Magnetic Resonance Imaging, Male, Middle Aged, Models, Biological, Regression Analysis, Thiazoles, Time Factors, Cohort Studies, Biomarkers, Age of Onset, Fluorodeoxyglucose F18, Positron-Emission Tomography
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Regional variability of imaging biomarkers in autosomal dominant Alzheimer's disease. https://app.cochat.ai/papers/10.1073/pnas.1317918110
- The paper
- Benzinger, T. L. S., Blazey, T., Jack, C. R., Koeppe, R. A., Su, Y., Xiong, C., Raichle, M. E., Snyder, A. Z., Ances, B. M., Bateman, R. J., Cairns, N. J., Fagan, A. M., Goate, A., Marcus, D. S., Aisen, P. S., Christensen, J. J., Ercole, L., Hornbeck, R. C., Farrar, A. M., . . . Morris, J. C. (2013). Regional variability of imaging biomarkers in autosomal dominant Alzheimer's disease. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.1317918110
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.